is tirzepatide and wegovy the same thing F.D.A. Approves New Obesity Drug That Will Compete With Dr. Osipova breaks down the

Andersen, H

It was originally developed by Eli Lilly as a research molecule and is widely characterized in the literature as a unitary triple receptor agonist with affinity for the glucagon-like peptide-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR)

Clinical guidelines recommend assessing dose tolerance and efficacy every 4 weeks before advancing to the next level

They can help you weigh the benefits against the potential for increased gastrointestinal side effects and suggest management strategies

Standard protocols begin at 2.5 mg weekly, with increases scheduled over four to twelve weeks depending on your response and tolerance